Vaccines and immunotherapy for staphylococcal infections

International Journal of Artificial Organs

Volumn 28, Issue 11, 2005, Pages 1157-1162

  Patti, Joseph M ^a  

^a Inhibitex Inc   (United States)

Author keywords

Adhesin; Monoclonal antibodies; MSCRAMM; Nosocomial infections; Passive immunization; Staphylococcus aureus

Indexed keywords

BACTERIA; IMPLANTS (SURGICAL); SURGERY;

ADHESIN; HEALTH CARE COSTS; HOSPITAL ACQUIRED INFECTION; MEDICAL DEVICES; MSCRAMM; NOSOCOMIAL INFECTION; PASSIVE IMMUNIZATION; SURGICAL PROCEDURES;

MONOCLONAL ANTIBODIES;

ADHESIN; ALTASTAPH; ANTIBIOTIC AGENT; AUREXIS; AUROGRAB; BIOMATERIAL; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; INH A21; MONOCLONAL ANTIBODY; PLACEBO; POLYSACCHARIDE VACCINE; QUINOLONE DERIVATIVE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; STAPHVAX; STAPHYLOCOCCUS VACCINE; TEFIBAZUMAB; UNCLASSIFIED DRUG; VANCOMYCIN; VERONATE;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; BACTERIAL STRAIN; BACTERIUM ADHERENCE; BACTERIUM CONTAMINATION; CANDIDA ALBICANS; CLINICAL TRIAL; COHORT ANALYSIS; DEVICE INFECTION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; DRUG TOLERABILITY; ENTEROCOCCUS; EXTRACELLULAR MATRIX; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOTHERAPY; INFECTION PREVENTION; INFECTION RISK; MAXIMUM PERMISSIBLE DOSE; MULTIDRUG RESISTANCE; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS;

EID: 30644480293     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880502801113     Document Type: Review

References (42)

1. Horan TC, Culver DH, Gaynes RP, Jarvis WR, Edwards JR, Reid CR. Nosocomial infections in surgical patients in the United States, January 1986-June 1992. National Nosocomial Infections Surveillance (NNIS) System. Infect Control Hosp Epidemiol 1993; 14: 73-80.
2. Whitehouse JD, Friedman ND, Kirkland KB, Richardson WJ, Sexton DJ. The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: Adverse quality of life, excess length of stay, and extra cost. Infect Control Hosp Epidemiol 2002; 23: 183-9.
3. Darouiche RO. Device-associated infections: A macroproblem that starts with microadherence. Clin Infect Dis 2001; 33: 1567-72.
4. Cabell CH, Heidenreich PA, Chu VH, et al. Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. Am Heart J 2004. 147: 582-6.
5. Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med 2004; 350: 1422-9.
6. Sivaratnam K, Duggan JM. Left ventricular assist device infections: Three case reports and a review of the literature. ASAIO J 2002 48: 2-7.
7. Cabell CH, Jollis JG, Peterson GE, et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med 2002; 162: 90-4.
8. Centers for Disease Control and Prevention (CDC). Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 565-7.
9. Centers for Disease Control and Prevention (CDC). Vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR Morb Mortal Wkly Rep 2004; 53: 322-3.
10. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-7.
11. Liu Y, Ames B, Gorovits E, et al. SdrX, a serine-aspartate repeat protein expressed by Staphylococcus capitis with collagen VI binding activity. Infect Immun 2004; 72: 6237-44.
12. Cucarella C, et al. Expression of the biofilm-associated protein interferes with host protein receptors of Staphylococcus aureus and alters the infective process. Infect Immun 2002; 70: 3180-6.
13. 2+-dependent inhibitory site. J Biol Chem 1998; 273: 6821-9.
14. Patti JM, House-Pompeo K, Boles JO, Garza N, Gurusiddappa S, Hook M. Critical residues in the ligandbinding site of the Staphylococcus aureus collagen-binding adhesin (MSCRAMM). J Biol Chem 1995; 270: 12005-11.
15. Schwarz-Linek U, Plevin MJ, Pickford AR, Hook M, Campbell ID, Potts JR. Binding of a peptide from a Streptococcus dysgalactiae MSCRAMM to the N-terminal F1 module pair of human fibronectin involves both modules. FEBS Lett 2001; 497: 137-40.
16. Joh D, Speziale P, Gurusiddappa S, Manor J, Hook M. Multiple specificities of the staphylococcal and streptococcal fibronectin-binding microbial surface components recognizing adhesive matrix molecules. Eur J Biochem 1998; 258: 897-905.
17. Speziale P, Joh D, Visai L, et al. A monoclonal antibody enhances ligand binding of fibronectin MSCRAMM (adhesin) from Streptococcus dysgalactiae. J Biol Chem 1996; 271: 1371-8.
18. Sillanpaa J, Xu Y, Nallapareddy SR, Murray BE, Hook M. A family of putative MSCRAMMs from Enterococcus faecalis. Microbiology 2004; 150: 2069-78.
19. Nallapareddy SR, Weinstock GM, Murray BE. Clinical isolates of Enterococcus faecium exhibit strain-specific collagen binding mediated by Acm, a new member of the MSCRAMM family. Mol Microbiol 2003; 47: 1733-47.
20. Wolz C, Goerke C, Landmann R, Zimmerli W, Fluckiger U. Transcription of clumping factor A in attached and unattached Staphylococcus aureus in vitro and during device-related infection. Infect Immun 2002; 70: 2758-62.
21. Colque-Navarro P, Palma M, Soderquist B, Flock JI, Mollby R. Antibody responses in patients with staphylococcal septicemia against two Staphylococcus aureus fibrinogen binding proteins: Clumping factor and an extracellular fibrinogen binding protein. Clin Diagn Lab Immunol 2000; 7: 14-20.
22. Siboo IR, Cheung AL, Bayer AS, Sullam PM. Clumping factor A mediates binding of Staphylococcus aureus to human platelets. Infect Immun 2001; 69: 3120-7.
23. Stutzmann Meier P, Entenza JM, Vaudaux P, Francioli P, Glauser MP, Moreillon P. Study of Staphylococcus aureus pathogenic genes by transfer and expression in the less virulent organism Streptococcus gordonii. Infect Immun 2001; 69: 657-64.
24. Que YA, Haefliger JA, Francioli P, Moreillon P. Expression of Staphylococcus aureus clumping factor A in Lactococcus lactis subsp. cremoris using a new shuttle vector. Infect Immun 2000; 68: 3516-22.
25. Moreillon P, Entenza JM, Francioli P, et al. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun 1995; 63: 4738-43.
26. Luong TT, Lee CY. Overproduction of type 8 capsular polysaccharide augments Staphylococcus aureus virulence. Infect Immun 2002; 70: 3389-95.
27. Watts A, Ke D, Wang Q, Pillay A, Nicholson-Weller A, Lee JC. Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect Immun 2005; 73: 3502-11.
28. Nilsson IM, Patti JM, Bremell T, Hook M, Tarkowski A. Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus mediated septic death. J Clin Invest 1998; 101: 2640-9.
29. Josefsson E, Hartford O, O'Brien L, Patti JM, Foster T. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 2001; 184: 1572-80.
30. Brouillette E, Lacasse P, Shkreta L, et al. DNA immunization against the clumping factor A (ClfA) of Staphylococcus aureus. Vaccine 2002; 20: 2348-57.
31. Shkreta L, Talbot BG, Diarra MS, Lacasse P. Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows. Vaccine 2004; 23: 114-26.
32. Flock M, Flock JI. Rebinding of extracellular adherence protein Eap to Staphylococcus aureus can occur through a surface-bound neutral phosphatase. J Bacteriol 2001; 183: 3999-4003.
33. Fattom A, Sarwar J, Ortiz A, Naso R. Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 1996; 64: 1659-65.
34. Lee J, Park J, Shepherd S. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 1997; 65: 4146-51.
35. Nemeth J, Lee JC. Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis. Infect Immun 1995; 63: 375-80.
36. Tollersrud T, Zernichow L, Andersen SR, Kenny K, Lund A. Staphylococcus aureus capsular polysaccharide type 5 conjugate and whole cell vaccines stimulate antibody responses in cattle. Vaccine 2001; 19: 3896-903.
37. Ma J, Cocchiaro J, Lee JC. Evaluation of serotypes of Staphylococcus aureus strains used in the production of a bovine mastitis bacterin. J Dairy Sci 2004; 87: 178-82.
38. Domanski PJ, Patel PR, Bayer AS, et al. Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus. Infect Immun 2005; 73: 5229-32.
39. Reilley S, W E, Reynolds L, Bennett B, Patti JM, Hetherington S. Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. Antimicrob Agents Chemother 2005; 49: 959-62.
40. Bloom BT, Kueser TJ, Oelberg DG, Bifano EM, White RD, Schelonka RL, Pearlman SA, Hetherington SV. A Phase 1 multicenter study and tolerance of a donor-selected staphylococcal immune globulin in very low birth weight infants. Pediatric Academic Societies Annual Meeting 2003. Seattle, Washington. Abstract 1804.
41. Bloom B, Schelonka R, Kueser T, et al. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J 2005; 24: 858-66.
42. Burnie JP, Matthews RC, Carter T, Beaulieu E, Donohoe M, Chapman C, Williamson P, Hodgetts SJ. Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infec Immun 2000; 68: 3200-9.